Abstract
Paritha Arumugam, Minzhe Guo, Claire Williams, Brenna Carey, Matthew Wessendarp, David Read, Dana Jackson, Jennifer Stock, Rathnakumar Kumaragurubaran, Grant Waterer, Cole Trapnell, Bruce C. Trapnell
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1053/joca.1998.0164
10.1053/joca.1998.0164
10.1378/chest.107.3_supplement.140s
10.1378/chest.107.3_supplement.140s
10.1172/jci28756
10.1172/jci28756
10.1164/ajrccm.164.7.2103011
10.1164/ajrccm.164.7.2103011
10.1148/radiology.212.3.r99se04637
10.1148/radiology.212.3.r99se04637
10.3389/fimmu.2024.1437767
10.3389/fimmu.2024.1437767
10.1016/j.cell.2024.05.021
10.1016/j.cell.2024.05.021
Bronchoalveolar Lavage Lymphocytes in the Diagnosis of Hypersensitivity Pneumonitis among Patients with Interstitial Lung Disease
10.1513/annalsats.202005-420oc · 2020
Bronchoalveolar lavage in hypersensitivity pneumonitis: a series of 139 patients
10.2174/187152812798889330 · 2012
10.1164/rccm.200308-1167oc
10.1164/rccm.200308-1167oc
10.1164/ajrccm/142.6_pt_1.1407
10.1164/ajrccm/142.6_pt_1.1407
10.1183/09031936.00150208
10.1183/09031936.00150208
10.1164/rccm.200608-1113oc
10.1164/rccm.200608-1113oc
10.1164/rccm.201906-1123oc
10.1164/rccm.201906-1123oc
10.1378/chest.122.6.2150
10.1378/chest.122.6.2150
10.1378/chest.11-1880
10.1378/chest.11-1880
STAT5b Deficiency: A Rare Cause of Pulmonary Alveolar Proteinosis
2019
10.1165/rcmb.2011-0392tr
10.1165/rcmb.2011-0392tr
10.1152/ajplung.00203.2014
10.1152/ajplung.00203.2014
10.1146/annurev.physiol.64.090601.113847
10.1146/annurev.physiol.64.090601.113847
10.1056/nejmra023226
10.1056/nejmra023226
Pulmonary alveolar proteinosis
10.1038/s41572-019-0066-3 · 2019
10.1126/science.8171324
10.1126/science.8171324
10.1073/pnas.91.12.5592
10.1073/pnas.91.12.5592
10.1182/blood.v56.6.947.947
10.1182/blood.v56.6.947.947
10.1016/s1074-7613(01)00218-7
10.1016/s1074-7613(01)00218-7
10.1084/jem.20131199
10.1084/jem.20131199
10.1084/jem.20210745
10.1084/jem.20210745
10.1038/ni.3005
10.1038/ni.3005
10.1073/pnas.92.21.9565
10.1073/pnas.92.21.9565
A murine model of hereditary pulmonary alveolar proteinosis caused by homozygous Csf2ra gene disruption
10.1152/ajplung.00175.2021 · 2022
10.1016/s1471-4906(02)02260-3
10.1016/s1471-4906(02)02260-3
10.1038/nri2356
10.1038/nri2356
10.1084/jem.176.6.1693
10.1084/jem.176.6.1693
10.1242/jcs.260298
10.1242/jcs.260298
10.1038/srep15566
10.1038/srep15566
Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis
10.1038/s41467-018-05491-z · 2018
10.1038/s41598-017-10879-w
10.1038/s41598-017-10879-w
10.1038/mi.2015.84
10.1038/mi.2015.84
10.4049/jimmunol.179.6.3488
10.4049/jimmunol.179.6.3488
10.1189/jlb.1a0314-170r
10.1189/jlb.1a0314-170r · doi-reference
10.1371/journal.pone.0279037
10.1371/journal.pone.0279037 · doi-reference
10.1371/journal.pone.0145342
10.1371/journal.pone.0145342 · doi-reference
10.1038/s41586-023-06720-2
10.1038/s41586-023-06720-2 · doi-reference
10.1038/s41586-019-0969-x
10.1038/s41586-019-0969-x · doi-reference
10.1126/science.aam8940
10.1126/science.aam8940 · doi-reference
10.1126/sciadv.adl4913
10.1126/sciadv.adl4913 · doi-reference
Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis
10.1164/rccm.201306-1039oc · doi-reference
10.1002/jlb.46.2.119
10.1002/jlb.46.2.119 · doi-reference
10.1016/j.mito.2021.10.009
10.1016/j.mito.2021.10.009 · doi-reference
10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2984
10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2984 · doi-reference
10.1038/s41467-023-44184-0
10.1038/s41467-023-44184-0 · doi-reference
10.1172/jci5212
10.1172/jci5212 · doi-reference
10.1016/j.ymthe.2019.06.010
10.1016/j.ymthe.2019.06.010 · doi-reference
10.1016/0002-9343(81)90577-5
10.1016/0002-9343(81)90577-5 · doi-reference
10.1038/ni973
10.1038/ni973 · doi-reference
10.1084/jem.20080759
10.1084/jem.20080759 · doi-reference
10.1084/jem.20080990
10.1084/jem.20080990 · doi-reference
10.1084/jem.190.6.875
10.1084/jem.190.6.875 · doi-reference
10.1016/1074-7613(95)90046-2
10.1016/1074-7613(95)90046-2 · doi-reference
10.1084/jem.119.1.167
10.1084/jem.119.1.167 · doi-reference
10.1038/nature13807
10.1038/nature13807 · doi-reference
10.1165/rcmb.2005-0241oc
10.1165/rcmb.2005-0241oc · doi-reference
10.4049/jimmunol.141.10.3383
10.4049/jimmunol.141.10.3383 · doi-reference
10.1182/blood.v98.9.2845
10.1182/blood.v98.9.2845 · doi-reference
10.1126/sciimmunol.abj0140
10.1126/sciimmunol.abj0140 · doi-reference
10.1016/j.immuni.2017.10.007
10.1016/j.immuni.2017.10.007 · doi-reference
10.4049/jimmunol.0803504
10.4049/jimmunol.0803504 · doi-reference
10.1038/nature03988
10.1038/nature03988 · doi-reference
PPAR gamma and PGC-1alpha activators protect against diabetic nephropathy by suppressing the inflammation and NF-kappaB activation
10.1111/nep.14381 · doi-reference
10.1152/ajpendo.90632.2008
10.1152/ajpendo.90632.2008 · doi-reference
10.1038/34178
10.1038/34178 · doi-reference